Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy
Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e009368
DOI: 10.1136/jitc-2024-009368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.07.2024. Verfasst von Haider Al-Janabi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Membrane Proteins, Macrophages. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK, Prostate Cancer UK.
Abstract (Originalsprache)
Background
Androgen deprivation therapy (ADT) is a front-line treatment for prostate cancer. In some men, their tumors can become refractory leading to the development of castration-resistant prostate cancer (CRPC). This causes tumors to regrow and metastasize, despite ongoing treatment, and impacts negatively on patient survival. ADT is known to stimulate the accumulation of immunosuppressive cells like protumoral tumor-associated macrophages (TAMs), myeloid-derived suppressor cells and regulatory T cells in prostate tumors, as well as hypofunctional T cells. Protumoral TAMs have been shown to accumulate around tumor blood vessels during chemotherapy and radiotherapy in other forms of cancer, where they drive tumor relapse. Our aim was to see whether such perivascular (PV) TAMs also accumulate in ADT-treated prostate tumors prior to CRPC, and, if so, whether selectively inducing them to express a potent immunostimulant, interferon beta (IFNβ), would stimulate antitumor immunity and delay CRPC.
Methods
We used multiplex immunofluorescence to assess the effects of ADT on the distribution and activation status of TAMs, CD8+T cells, CD4+T cells and NK cells in mouse and/or human prostate tumors. We then used antibody-coated, lipid nanoparticles (LNPs) to selectively target a STING agonist, 2′3′-cGAMP (cGAMP), to PV TAMs in mouse prostate tumors during ADT.
Results
TAMs accumulated at high density around blood vessels in response to ADT and expressed markers of a protumoral phenotype including folate receptor-beta (FR-β), MRC1 (CD206), CD169 and VISTA. Additionally, higher numbers of inactive (PD-1-) CD8+T cells and reduced numbers of active (CD69+) NK cells were present in these PV tumor areas. LNPs coated with an antibody to FR-β selectively delivered cGAMP to PV TAMs in ADT-treated tumors, where they activated STING and upregulated the expression of IFNβ. This resulted in a marked increase in the density of active CD8+T cells (along with CD4+T cells and NK cells) in PV tumor areas, and significantly delayed the onset of CRPC. Antibody depletion of CD8+T cells during LNP administration demonstrated the essential role of these cells in delay in CRPC induced by LNPs.
Conclusion
Together, our data indicate that targeting a STING agonist to PV TAMs could be used to extend the treatment window for ADT in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK.
- The Institute of Cancer Research, London, UK.
- The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, UK.
- NeoGenomics Laboratories Inc Aliso Viejo, Aliso Viejo, California, USA.
- Lipexogen Biotech, Baltimore, Maryland, USA.
- Division of Clinical Medicine, The University of Sheffield, Sheffield, UK.
ORCID-Profile: Wayne A Phillips, Claire E Lewis
Förderung
- Cancer Research UK
- Prostate Cancer UK
Zitieren
APA
Al-Janabi, H., Moyes, K., Allen, R., Fisher, M., Crespo, M., Gurel, B., Rescigno, P., de Bono, J., Nunns, H., Bailey, C., Junker-Jensen, A., Muthana, M., Phillips, W. A., Pearson, H. B., Taplin, M. E., Brown, J. E., & Lewis, C. E. (2024). Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7), e009368. https://doi.org/10.1136/jitc-2024-009368
Vancouver
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, et al. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer. 2024;12(7):e009368. doi:10.1136/jitc-2024-009368
BibTeX
@article{AlJanabi2024,
author = {Al-Janabi, Haider and Moyes, Katy and Allen, Richard and Fisher, Matthew and Crespo, Mateus and Gurel, Bora and Rescigno, Pasquale and de Bono, Johann and Nunns, Harry and Bailey, Christopher and Junker-Jensen, Anna and Muthana, Munitta and Phillips, Wayne A and Pearson, Helen B and Taplin, Mary-Ellen and Brown, Janet E and Lewis, Claire E},
title = {Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {7},
pages = {e009368},
doi = {10.1136/jitc-2024-009368}
}
EUVIMED